Bio-Largo, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Bio-Largo, Inc. has filed its 2023 Form 10-K detailing its financial performance and business operations.</b>

AI Summary

BIOLARGO, INC. (BLGO) filed a Annual Report (10-K) with the SEC on April 1, 2024. Bio-Largo, Inc. reported its 2023 fiscal year-end results on Form 10-K. The company's fiscal year concluded on December 31, 2023. The filing includes financial data and business operations for the period. Bio-Largo, Inc. is categorized under Chemicals & Allied Products. The company's principal executive offices are located in Westminster, California.

Why It Matters

For investors and stakeholders tracking BIOLARGO, INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Bio-Largo's financial health, operational status, and strategic direction for the fiscal year 2023, crucial for investors to assess the company's performance and future prospects. As a public company, Bio-Largo is required to disclose detailed financial and operational information annually, offering transparency to shareholders and the market regarding its business activities and compliance with SEC regulations.

Risk Assessment

Risk Level: medium — BIOLARGO, INC. shows moderate risk based on this filing. The company's financial performance and operational details are presented in a standard 10-K filing, which typically contains forward-looking statements and risk factors that require careful investor scrutiny. Specific financial figures and growth rates are not detailed in the provided header information, necessitating a deeper review of the full document.

Analyst Insight

Investors should review the full 10-K filing to understand Bio-Largo's financial performance, revenue streams, debt obligations, and risk factors for fiscal year 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-04-01 — Filing Date (Date the 10-K was filed)
• 0.17 — Common Stock Price (As of December 31, 2023)

Key Players & Entities

• BIOLARGO, INC. (company) — Filer name
• BLGO (company) — Ticker symbol
• 2024-04-01 (date) — Filing date
• 2023-12-31 (date) — Period of report
• 14921 CHESTNUT ST. (address) — Business address
• WESTMINSTER (location) — Business address city
• CA (location) — Business address state
• 92683 (postal_code) — Business address zip

FAQ

Industry Context

Bio-Largo, Inc. operates within the Chemicals & Allied Products industry. This sector involves the manufacturing and distribution of chemical products and related goods.

Regulatory Implications

As a publicly traded company, Bio-Largo, Inc. is subject to the reporting requirements of the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.

What Investors Should Do

1. Review Bio-Largo's full 10-K for detailed financial statements and management discussion.
2. Analyze the company's revenue, expenses, and profitability for fiscal year 2023.
3. Assess the identified risk factors and their potential impact on the company's future operations.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-04-01: Filing Date — Date Bio-Largo, Inc. submitted its 10-K to the SEC.

Year-Over-Year Comparison

This is the initial filing data provided for the 2023 10-K. Comparative data from the previous year's filing is not available in this header information.

Filing Documents

• blgo20231231_10k.htm (10-K) — 1799KB
• ex_648185.htm (EX-10.1) — 128KB
• ex_648186.htm (EX-10.2) — 91KB
• ex_599061.htm (EX-21.1) — 3KB
• ex_637579.htm (EX-23.1) — 3KB
• ex_599062.htm (EX-23.2) — 3KB
• ex_599063.htm (EX-31.1) — 12KB
• ex_599064.htm (EX-31.2) — 12KB
• ex_599065.htm (EX-32) — 6KB
• 0001437749-24-010394.txt (&nbsp;) — 9731KB
• blgo-20231231.xsd (EX-101.SCH) — 76KB
• blgo-20231231_cal.xml (EX-101.CAL) — 50KB
• blgo-20231231_def.xml (EX-101.DEF) — 609KB
• blgo-20231231_lab.xml (EX-101.LAB) — 470KB
• blgo-20231231_pre.xml (EX-101.PRE) — 636KB
• blgo20231231_10k_htm.xml (XML) — 1623KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 9 Item 1B. Unresolved Staff Comments 20 Item 1C. Cybersecurity 20 Item 2.

Properties

Properties 20 Item 3.

Legal Proceedings

Legal Proceedings 20 Item 4. Mine Safety Disclosures 20 PART II. Item 5. Market for Registrant's Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities 21 Item 6.

Selected Financial Data

Selected Financial Data 22 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 29 Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 29 Item 9A.

Controls and Procedures

Controls and Procedures 30 Item 9B. Other Information 31 PART III. Item 10. Directors, Executive Officers, and Corporate Governance 32 Item 11.

Executive Compensation

Executive Compensation 32 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 32 Item 13. Certain Relationships and Related Transactions, and Director Independence 32 Item 14. Principal Accounting Fees and Services 32 PART IV. Item 15. Exhibits, Financial Statement Schedules 33

Signatures

Signatures 37 Index to Financial Statements F-1 Report of Independent Registered Public Accounting Firm F-2 Consolidated Financial Statements for the Years Ended December 31, 2023 and 2022 F-9 Table of Contents PART I

BUSINESS

ITEM 1. BUSINESS USE OF FORWARD-LOOKING STATEMENTS IN THIS REPORT This annual report on Form 10-K for the year ended December 31, 2023 (the "Annual Report") contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this Annual Report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These forward-looking statements include, but are not limited to, predictions regarding: our business plan; the commercial viability of our technology and products incorporating our technology; the effects of competitive factors on our technology and products incorporating our technology; expenses we will incur in operating our business; our liquidity and sufficiency of existing cash; the success of our financing plans; and the outcome of pending or threatened litigation. You can identify these and other forward-looking statements by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions, or the negative of such terms, although not all forward-looking statements contain these identifying words. Forward-looking statements also include the assumptions underlying or relating to any of the foregoing statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements included in this Annual Report; particularly, the section titl

View Full Filing

View this 10-K filing on SEC EDGAR